Deaf or dead? Better drugs needed to stop drug-resistant TB

Deaf or dead? Better drugs needed to stop drug-resistant TB 13.06.2012 Kerry Cullinan

This has emerged as one of the key issues at the third South African tuberculosis conference, which opened last night (Tues) in Durban.

At present, people with drug-resistant TB face almost two years of treatment, including a daily injection for the first six months.

Despite this punishing regimen, less than half the cases of drug-resistant TB were cured in South Africa last year, according to the World Health Organisation. A number of patients also stop treatment because they cannot tolerate the side effects.

Treatment for drug-resistant TB is ineffective. It is too long, there are significant side-effects and it is expensive, according to Dr Helen Cox of Medicins sans Frontieres.

Aside from the daily injections that are very painful, 30 percent of people with drug-resistant TB develop hearing loss that is irreversible as a side-effect of the drugs, said Cox.

If someone starts going deaf a few weeks into treatment, what do we do? They need to continue with their treatment, but this means they will either be deaf or dead. This highlights the urgent need for new drugs.

The Treatment Action Campaign, Section27 and Oxfam, called for patients with drug-resistant TB who were failing to respond to treatment to be given access to the best available medicines.

The organisations argued for such patients to get compassionate access to new, promising medicines not yet approved by the Medicines Control Council, including Linezolid, Bedaquiline and Delaminid.

The organisation delivered a memorandum containing five demands to conference organisers shortly before the opening.

See the original post here:
Deaf or dead? Better drugs needed to stop drug-resistant TB